Company Overview and News
QUÉBEC, 29 août 2018 (GLOBE NEWSWIRE) -- Nemaska Lithium Inc. (« Nemaska Lithium » ou la « société ») (TSX:NMX) (OTCQX:NMKEF) (FRANCFORT:N0T) est heureuse de confirmer qu’elle a satisfait les conditions requises avant la date butoir (telle que définie aux modalités des obligations) en vertu de son placement d’obligations garanties et remboursables de premier rang de 350 millions US$ (les « obligations ») dont la clôture a été annoncée le 30 mai dernier (le « placement d’obligations »).
QUÉBEC CITY, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Nemaska Lithium Inc. (“Nemaska Lithium” or the “Corporation”) (TSX:NMX) (OTCQX:NMKEF) (FRANCFORT:N0T) is pleased to confirm that it has satisfied the conditions required before the the Long Stop Date (as defined in the terms of the Bonds) pursuant to its offering of senior secured callable bonds in the aggregate principal amount of USD 350M (the "Bonds"), the completion of which was announced on May 30, 2018 (the "Bond Offering").
NMX TXTW NMKEF
PHOENIX, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Nemaska Lithium, Inc., (OTCQB:NMKEF) (the “Company”) CEO Guy Bourassa is making another stop on Uptick Newswire’s “Stock Day” podcast with Everett Jolly.
NMX TXTW QBC NMKEF
Lithium market news - The Benchmark Minerals megafactory tracker is now at 41 in the pipeline.
LIT BCN PILBF LTHHF CXO SAV LAXXF LIACF AGY NMT PLLLY RDRUY AZZVF MS WML SQM MLNLF AIS.H KDR SYA STLHF WMLLF LNRDY NGZ AMVMF LMMFF GXY TAW LRS MNIKF ILHMF AMLM ALB DMNXF MALRY BGS LACDF EEYMF MIN NMKEF ARYMF ILC GALXF MGXMF LSSCF ALTAF DJIFF NMX EMH PSC CRECF OROCF ERPNF LAC PLS BCN TWNAF DJI RRSSF PDDTF NTTHF TSLA MALRF ORE AVZ AJM BCRMF
QUÉBEC, 23 août 2018 (GLOBE NEWSWIRE) -- Nemaska Lithium Inc. (« Nemaska Lithium » ou la « Société ») (TSX: NMX) (OTCQX: NMKEF) (FRANCFORT: N0T) est heureuse de confirmer que Nemaska Lithium Shawinigan Transformation Inc., sa filiale à part entière, a reçu un premier versement de 75M US$ de filiales d’Orion Mine Finance II LP (« Orion ») en vertu de l’entente sur la production (communément désignée « streaming ») conclue le 12 avril 2018 (l’« entente sur la production »).
QUEBEC CITY, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Nemaska Lithium Inc. (“Nemaska Lithium” or the “Corporation”) (TSX: NMX) (OTCQX: NMKEF) (FRANKFURT: N0T) is pleased to confirm that Nemaska Lithium Shawinigan Transformation Inc., its wholly-owned subsidiary, has received a first payment of USD 75M from affiliates of Orion Mine Finance II LP (“Orion”) under the streaming agreement entered into on April 12, 2018 (the “Streaming Agreement”).
NMX TXTW NMKEF
QUÉBEC, 20 août 2018 (GLOBE NEWSWIRE) -- Nemaska Lithium Inc. (« Nemaska Lithium » ou la « Société ») (TSX:NMX) (OTC:NMKEF) et Northvolt AB (« Northvolt ») sont heureuses d’annoncer la signature d’un contrat visant l’approvisionnement d’hydroxyde de lithium de qualité batterie par la Société à Northvolt.
QUEBEC CITY, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Nemaska Lithium Inc. (“Nemaska Lithium” or the “Corporation”) (TSX:NMX) (OTC:NMKEF) and Northvolt AB ("Northvolt") are pleased to announce the signature of an agreement providing for the supply of battery grade lithium hydroxide by the Corporation to Northvolt.
NMX TXTW NMKEF
Lithium market - Goldman: Concerns about a wave of supply of the electric car battery material from new mines are unfounded. The selloff in companies tied to lithium is overdone.
LIT BCN PILBF LTHHF CXO SAV LAXXF LIACF AGY NMT KSN PLLLY RDRUY AZZVF WML MLNLF AIS.H KDR DFS SYA STLHF WMLLF LNRDY NGZ LMMFF GXY TAW LRS MNIKF ILHMF AMLM DMNXF MALRY BGS LACDF EEYMF MIN NMKEF ARYMF ILC GALXF MGXMF LSSCF ALTAF DJIFF NMX EMH PSC CRECF OROCF ERPNF LAC PLS FTI.WI FMC BCN TWNAF DJI RRSSF PDDTF NTTHF AVLIF MALRF ORE AVZ AJM BCRMF
2018-07-23 seekingalpha - 1
Piedmont Lithium (PLLL) is a junior miner looking to develop a lithium project in North Carolina's Tin-Spodumene Belt, a historic lithium mining region where the likes of Albemarle (ALB) and FMC (FMC) still have processing facilities. An Australian company, Piedmont Lithium trades primarily on the Australian Securities Exchange (ASX) under the ticker symbol PLL.AU. Since May 2018, the shares have also been available on the NASDAQ under the ticker PLLL.
PDDTF ALB NMX NMKEF
QUEBEC CITY, Quebec, July 23, 2018 (GLOBE NEWSWIRE) -- Nemaska Lithium Inc. (“Nemaska Lithium” or the “Corporation”) (TSX:NMX) (OTC:NMKEF) is very pleased to provide a project construction update and development timeline for its Whabouchi Mine and Electrochemical Plant in Shawinigan. Moving forward, Nemaska Lithium intends to issue progress reports in conjunction with its quarterly and annual financial reporting.
NMX TXTW NMKEF
QUÉBEC, Québec, 23 juill. 2018 (GLOBE NEWSWIRE) -- Nemaska Lithium Inc. (« Nemaska Lithium » ou la « Société ») (TSX:NMX) (OTC:NMKEF) a le grand plaisir de présenter une mise à jour sur la construction et l’échéancier des projets du site minier Whabouchi et de l’usine électrochimique de Shawinigan. Désormais, Nemaska Lithium a l’intention de publier des rapports d’étape en conjonction avec ses rapports financiers trimestriels et annuels.
2018-07-16 seekingalpha - 3
Similar to much of its peers, the share price of NMKEF has taken a hit. Behind the scenes, the company has been busy doing work to push development forward.
SFTBF JMPLF NMKEF NMX JMPLY 9984 MS SFTBY
16h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
16h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
18h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET